NYSE
$13.75▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $3.61BShares out 2.600M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 8.12Regular26.08.13 02:014Ownership#●●●#●●●
Organon & Co.
Juan Camilo Arjona Ferreira, an executive at Organon & Co., filed a Form 4 report on August 11, 2026, regarding changes in beneficial ownership of company securities. This filing serves as a standard disclosure of insider equity transactions to the market.…more
$13.75+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.5After-hours26.08.06 05:26144Ownership
Organon & Co.
Organon & Co.의 내부자인 Juliana Papa가 2026년 8월 5일 SEC Form 144를 통해 자사 주식 매도를 신고했습니다. 이는 내부자가 보유한 주식을 시장에 매각하겠다는 의사를 공식적으로 표명한 것입니다.…more
$13.75+0.00%vs prev closeView filingShare - 8.5After-hours26.08.06 05:044Ownership
Organon & Co.
오가논(Organon & Co.)의 내부자인 줄리아나 파파 드라이네(Juliana Papa Drinane)가 2026년 8월 5일 자로 주식 소유 변동 보고서인 Form 4를 제출했습니다. 본 공시는 내부자의 지분 보유 현황 변경을 공식화한 것으로, 투자자는 해당 임원의 지분 변동 내역을 확인해야 합니다.…more
$13.75+0.00%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.16Pre-market26.10.16 20:34#●●●#●●●
Organon to Present Phase 3 Data for MIUDELLA IUD at 2026 SFP Meeting
Organon will present interim Phase 3 results for its hormone-free copper IUD, MIUDELLA, at the 2026 Society of Family Planning Annual Meeting. The data highlights the efficacy and safety of the device over six years of use following the company's global licensing deal.…more
$13.75+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.28Pre-market26.09.28 21:09
●●●●●●●● ●●●●● ●●●●●●
Organon Canada has announced the approval and availability of NDUVRA, a topical cream for treating moderate to severe atopic dermatitis. The treatment is indicated for both adult and pediatric patients aged 2 years and older.…more
$13.75+0.00%vs prev closeShareBenzinga - 9.14Pre-market26.09.14 20:35
●●●●●●●● ●●●●● ●●●●●●
The FDA has accepted for review the supplemental New Drug Application to extend the duration of use for the MIUDELLA copper IUD from 3 to 6 years. A final decision on the application is expected in the second quarter of 2027.…more
$13.75+0.00%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report